Drug Trial Radar · NCT06164327
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Dec 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
75
Planned (sponsor's estimate)
Start
Dec 1, 2023
Primary completion
Oct 31, 2025
Study completion Nov 5, 2025
Sponsor
- Lead sponsor
- BeBetter Med IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open Phase Ib clinical study to evaluate the safety,efficacy and pharmacokinetics of BEBT-908 combined with Rituximab (R) or combined with Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) or combined with Rituximab-Ifosfamide-Carboplatin-Etoposide (R-ICE) in the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).
Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Interventions
BEBT-908 for InjectionDrug
BEBT-908 for Injection,dosage of administration:15mg/m\^2 or 22.5mg/m\^2,frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.
Rituximab InjectionDrug
Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle.
Gemcitabine Hydrochloride for InjectionDrug
Gemcitabine Hydrochloride for Injection,dosage of administration:1g/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
Oxaliplatin InjectionDrug
Oxaliplatin Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
Etoposide InjectionDrug
Etoposide Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle,and 21 days as a cycle.
Ifosfamide for InjectionDrug
Ifosfamide for Injection,dosage of administration:5000mg/m\^2,24 hours of continuous intravenous drip,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
Carboplatin InjectionDrug
Carboplatin Injection,dosage of administration:based on AUC=5, single dose ≤800 mg,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: Every 6 weeks,assessed up to 24 months.
- AETime frame: From the first administration of the study drug to 28 days after the last administration of the study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.